Skip to main content
. 2013 May 31;7:435–448. doi: 10.2147/DDDT.S31504

Figure 2.

Figure 2

Key milestones in the lifecourse of osteoporosis therapy. Strontium ranelate is not approved by the FDA but all other agents have been approved both by the FDA and EMA.

Note: The dates shown represent the year that they were first approved by the FDA (or EMA for strontium ranelate) for use in the treatment of osteoporosis.

Abbreviations: EMA, European Medicines Agency; FDA, US Food and Drug Administration; IV, intravenous.